The Creative Gene: IP, IT and life sciences.
The unpredictable nature of the biotech sector means innovative new structures are required to stimulate deal flow and improve access to finance for start-ups. Janita Good reports
Life science companies, particularly biotechs, are difficult to fund. In part, this is due to a mismatch between their funding needs and the main financial sources. Private equity and venture capital funds (VCs) must typically place and recoup investment in five to seven years, whereas the cost of getting a drug to market can run to $800m (£427m) and take 10 or more years.
This premium content is reserved for
Legal Week Subscribers.
Subscribe today and get 10% off.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Unique access to ALM's unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week's UK Top 50 and Global 100 rankings
- The Legal Week Daily News Alert, Editor's Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now
For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651